Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL

Exclusion Criteria

• •1. administration of blinatumomab therapy for more than 14 days;
• •2. patients with leukemia burden ≥ 10% before initiation of treatment;
• •3. patients with severe organ dysfunctions before treatment, including myocardial infarction, chronic heart failure, decompensated liver dysfunction, renal dysfunction, or gastrointestinal dysfunction;
• •4. patients with central nervous system leukemia.